The Relationship between Erectile Dysfunction and Lower Urinary Tract Symptoms and the Role of Phosphodiesterase Type 5 Inhibitors

European Urology

Volumn 55, Issue 1, 2009, Pages 38-48

  Köhler, Tobias S ^a   McVary, Kevin T ^b  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Erectile dysfunction; Lower urinary tract symptoms; Phosphodiesterase inhibitors

Indexed keywords

ALFUZOSIN; CYCLIC GMP; ENDOTHELIN; MESSENGER RNA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NORADRENALIN; PHOSPHODIESTERASE; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; RHO KINASE; SILDENAFIL; STEROID 5ALPHA REDUCTASE INHIBITOR; TADALAFIL; TAMSULOSIN; VARDENAFIL;

AGING; ATHEROSCLEROSIS; AUTONOMIC NERVOUS SYSTEM; BLADDER; BLADDER NECK STENOSIS; CIGARETTE SMOKING; CORPUS CAVERNOSUM; DIABETES MELLITUS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG MECHANISM; DYSLIPIDEMIA; ENZYME INHIBITION; ERECTILE DYSFUNCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LOWER URINARY TRACT SYMPTOM; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; REVIEW; RISK FACTOR; SCREENING; UNSPECIFIED SIDE EFFECT; URETHRA;

AUTONOMIC NERVOUS SYSTEM; CLINICAL TRIALS AS TOPIC; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; ERECTILE DYSFUNCTION; HUMANS; MALE; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITORS; PROSTATISM;

EID: 56249104747     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.08.062     Document Type: Review

References (50)

1. Uckert S., Küthe A., Jonas U., and Stief C.G. Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 166 (2001) 2484-2490
2. Podlasek C.A., Zelner D.J., McKenna K.E., and McVary K.T. Morphological changes and altered NOS isoform distribution in the BB/WOR diabetic rat prostate. J Urol 169 (2003) 396 abstract 1108
3. Filippi S., Morelli A., Sandner P., et al. Characterization and functional role of an androgen-dependent PDE5 activity in the bladder. Endocrinology 148 (2007) 1019-1029
4. Tinel H., Stelte-Ludwig B., Hutter J., and Sandner P. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int 98 (2006) 1259-1263
5. Guh J.H., Hwang T.L., Ko F.N., Chueh S.C., Lai M.K., and Teng C.M. Antiproliferative effect in human prostatic smooth muscle cells by nitric oxide donor. Mol Pharmacol 53 (1998) 467-474
6. Hammarsten J., and Hogstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press 8 (1999) 29-36
7. Meigs J.B., Mohr B., Barry M.J., Collins M.M., and McKinlay J.B. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 54 (2001) 935-944
8. McVary K.T., Razzaq A., Lee C., et al. Growth of the rat prostate gland is facilitated by the autonomic nervous system. Biol Reprod 51 (1994) 99-107
9. Hale T.M., Okabe H., Bushfield T.L., Heaton J.P., and Adams M.A. Recovery of erectile function after brief aggressive antihypertensive therapy. J Urol 168 (2002) 348-354
10. Rahman N.U., Phonsombat S., Bochinski D., Carrion R.E., Nunes L., and Lue T.F. An animal model to study lower urinary tract symptoms and erectile dysfunction: the hyperlipidemic rat. BJU Int 100 (2007) 658-663
11. McVary K.T., Rademaker A., Lloyd G.L., and Gann P. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 174 (2005) 1327-1433
12. Holmquist F., Andersson K.E., and Hedlund H. Actions of endothelin on isolated corpus cavernosum from rabbit and man. Acta Physiol Scand 139 (1990) 113-122
13. Azadzoi K.M., Kim N., Brown M.L., Goldstein I., Cohen R.A., and Saenz de Tejada I. Endothelium-derived nitric oxide and cyclooxygenase products modulate corpus cavernosum smooth muscle tone. J Urol 147 (1992) 220-225
14. Lue T.F. Physiology of penile erection and pathophysiology of erectile dysfunction and priapism. In: Wein P.C. (Ed). Campbell's Urology. 8th ed (2002), Saunders, Philadelphia PA 187-190
15. Uckert S., Sormes M., Kedia G., et al. Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue. Urology 71 (2008) 526-530
16. Ahn G.J., Yu J.Y., Choi S.M., et al. Chronic administration of phosphodiesterase 5 inhibitor improves erectile and endothelial function in a rat model of diabetes. Int J Androl 28 (2005) 260-266
17. Rees R.W., Ziessen T., Ralph D.J., Kell P., Moncada S., and Cellek S. Human and rabbit cavernosal smooth muscle cells express Rho-kinase. Int J Impot Res 14 (2002) 1-7
18. Wingard C.J., Husain S., Williams J., and James S. RhoA-Rho kinase mediates synergistic ET-1 and phenylephrine contraction of the rat corpus cavernosum. Am J Physiol Regul Integr Comp Physiol 285 (2003) 1145-1152
19. Chang S., Hypolite J.A., Zderic S.A., Wein A.J., Chacko S., and DiSanto M.E. Enhanced force generation by corpus cavernosum smooth muscle in rabbits with partial bladder outlet obstruction. J Urol 167 (2002) 2636-2644
20. Bing W., Chang S., Hypolite J.A., et al. Obstruction-induced changes in urinary bladder smooth muscle contractility: a role for Rho kinase. Am J Physiol Renal Physiol 285 (2003) F990-F997
21. Rajasekaran M., White S., Baquir A., and Wilkes N. Rho-kinase inhibition improves erectile function in aging male Brown-Norway rats. J Androl 26 (2005) 182-188
22. Tarcan T., Azadzoi K.M., Siroky M.B., Goldstein I., and Krane R.J. Age related erectile and voiding dysfunction: the role of arterial insufficiency. Brit J of Urol 82 (1998) 26-33
23. Ponholzer A., Temml C., Wehrberger C., Marszalek M., and Maderbacher S. The association between LUTS and vascular risk factors in both sexes. Eur Urol 50 (2006) 581-586
24. Sairam K., Kulinskaya E., McNicholas T.A., Boustead G.B., and Hanbury D.C. Sildenafil improves lower urinary tract symptoms. BJU Int 90 (2002) 836-839
25. Mulhall J.P., Guhring P., Parker M., and Hopps C. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 3 (2006) 662-667
26. McVary K.T., Monnig W., Camps J.L., et al. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 177 (2007) 1071-1077
27. Stief C.G., Porst H., Neuser D., Beneke M., and Ulbrich E. A randomised placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 53 (2008) 1236-1244
28. McVary K.T., Roehrborn C.G., Kaminetsky J.C., et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 177 (2007) 1401-1407
29. Roehrborn C.G., McVary K.T., Elion-Mboussa A., and Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 180 (2008) 1228-1234
30. Roehrborn R.C. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo controlled trial. Urology 58 (2001) 953-959
31. Klotz T., Mathers M.J., Bloch W., Nayal W., and Engelmann U. Nitric oxide based influence of nitrates on micturition in patients with benign prostatic hyperplasia. Int Urol Nephrol 31 (1999) 335-341
32. Gacci M., Del Populo G., Macchiarella A., et al. Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study. J Urol 178 (2007) 2040-2043
33. Moreira Jr. E.D., Lbo C.F., Diament A., Nicolosi A., and Glasser D.B. Incidence of erectile dysfunction in men 40 to 69 years old: results from a population-based cohort study in Brazil. Urology 61 (2003) 431-436
34. Shiri R., Hakkinen J.T., Hakama M., et al. Effect of lower urinary tract symptoms on the incidence of erectile dysfunction. J Urol 174 (2005) 205-209
35. Chai T.C., Belville W.D., McGuire E.J., et al. Specificity of the American Urological Association Voiding Symptom Index: comparison of unselected and selected samples of both sexes. J Urol 150 (1993) 1710-1713
36. Brookes S.T., Link C.L., Donovan J.L., and McKinlay J.B. Relationship between lower urinary tract symptoms and erectile dysfunction: results from the Boston area community health survey. J Urol 179 (2008) 250-255
37. McVary K.T., Foley K.A., Long S.R., et al. Identifying patients with benign prostatic hyperplasia through a diagnosis of, or treatment for, erectile dysfunction. Curr Med Res Opin 24 (2008) 775-784
38. Braun M., Wassamer G., Klotz T., et al. Epidemiology of erectile dysfunction: results of the Cologne Male Survey. Int J Impot Res 12 (2000) 305-311
39. Blanker M.H., Bohnen A.M., Groeneveld F.P., et al. Correlates for erectile dysfunction and ejaculatory dysfunction in older Dutch men: a community-based study. J Am Geriatr Soc 49 (2001) 436-442
40. Boyle P., Robertson C., Mazeta C., and Keech M. The association between lower urinary tract symptoms and erectile dysfunction in four centres; the UrEpik study. BJU Int 92 (2003) 719-725
41. Vallancien G., Emberton M., Harving N., et al. Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. J Urol 169 (2003) 2257-2261
42. Rosen R., Altwein J., Boyle P., et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 44 (2003) 637-649
43. Braun M.H., Sommer F., Haupt G., Mathers M.J., Reifenrath B., and Engelmann U.S. Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical "aging male" symptoms? Results of the "Cologne Male Survey". Eur Urol 44 (2003) 588-594
44. Chung W.S., Nehra A., Jacobson D.J., et al. Lower urinary tract symptoms and sexual dysfunction in community-dwelling men. Mayo Clin Proc 79 (2004) 745-749
45. Ponholzer A., Temml C., Obermayr R., and Madersbacher S. Association between lower urinary tract symptoms and erectile dysfunction. Urology 64 (2004) 772-776
46. Hansen B.L. Lower urinary tract symptoms (LUTS) and sexual function in both sexes. Eur Urol 46 (2004) 229-234
47. Elliot S.P., Gulati M., Pasta D.J., et al. Obstructive lower urinary tract symptoms correlate with erectile dysfunction. Urology 63 (2004) 1148-1152
48. Terai A., Ichioka K., Matsui Y., and Yoshimura K. Association of lower urinary tract symptoms with erectile dysfunction in Japanese men. Urology 64 (2004) 132-136
49. McVary K.T., Foley J., Slawin K., et al. The long-term effects of doxazosin, finasteride, and the combination on sexual function in men participating in the MTOPS trial. J Urol 171 (2004) 1194 abstract
50. Paick S.H., Meehan A., Lee M., et al. The relationship among lower urinary tract symptoms, prostate specific antigen and erectile dysfunction in men with benign prostatic hyperplasia: results from the Proscar Long-Term Efficacy and Safety Study. J Urol 173 (2005) 903-907